US5719147A
(en)
*
|
1992-06-29 |
1998-02-17 |
Merck & Co., Inc. |
Morpholine and thiomorpholine tachykinin receptor antagonists
|
JPH10500944A
(ja)
*
|
1994-05-05 |
1998-01-27 |
メルク シヤープ エンド ドーム リミテツド |
モルホリン誘導体及びタキキニンのアンタゴニストとしてのそれらの使用
|
DK0777659T3
(da)
*
|
1994-08-15 |
2001-09-03 |
Merck Sharp & Dohme |
Morpholinderivater og deres anvendelse som terapeutiske midler
|
GB9417956D0
(en)
*
|
1994-09-02 |
1994-10-26 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9426104D0
(en)
*
|
1994-12-23 |
1995-02-22 |
Merck Sharp & Dohme |
Use of surfactants and emulsions
|
GB9505491D0
(en)
*
|
1995-03-18 |
1995-05-03 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9513972D0
(en)
*
|
1995-07-08 |
1995-09-06 |
Merck Sharp & Dohme |
Pharmaceutical compositions
|
GB9523244D0
(en)
*
|
1995-11-14 |
1996-01-17 |
Merck Sharp & Dohme |
Therapeutic agents
|
US5891875A
(en)
*
|
1996-05-20 |
1999-04-06 |
Eli Lilly And Company |
Morpholinyl tachykinin receptor antagonists
|
AU3716997A
(en)
|
1996-07-17 |
1998-02-09 |
Merck & Co., Inc. |
Alteration of circadian rhythmicity with a tachykinin antagonist
|
US6117855A
(en)
|
1996-10-07 |
2000-09-12 |
Merck Sharp & Dohme Ltd. |
Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
|
US6100256A
(en)
*
|
1996-12-02 |
2000-08-08 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptors antagonists for treating schizophrenic disorders
|
US6114315A
(en)
*
|
1996-12-02 |
2000-09-05 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
|
DE69731657T2
(de)
*
|
1996-12-02 |
2005-12-01 |
Merck Sharp & Dohme Ltd., Hoddesdon |
Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen
|
JP2001505881A
(ja)
*
|
1996-12-02 |
2001-05-08 |
メルク シヤープ エンド ドーム リミテツド |
精神分裂症疾患を治療するためのnk−1受容体拮抗薬の使用
|
WO1998024441A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety
|
DK0942729T3
(da)
*
|
1996-12-02 |
2005-01-10 |
Merck Sharp & Dohme |
Anvendelse af NK-1-receptorantagonister til behandling af stresslidelser
|
ES2234039T3
(es)
*
|
1996-12-02 |
2005-06-16 |
MERCK SHARP & DOHME LTD. |
Uso de antagonistas del receptor nk-1 para tratar trastornos de depresion mayor.
|
AU729708B2
(en)
*
|
1996-12-02 |
2001-02-08 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating severe anxiety disorders
|
DE69733148T2
(de)
*
|
1996-12-02 |
2006-02-02 |
Merck Sharp & Dohme Ltd., Hoddesdon |
Die verwendung von nk-1 rezeptorantagonisten für die behandlung von kognitiven störungen
|
US6613765B1
(en)
|
1996-12-02 |
2003-09-02 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating major depressive disorders
|
JP2001504851A
(ja)
*
|
1996-12-02 |
2001-04-10 |
メルク シヤープ エンド ドーム リミテツド |
性的機能不全の治療のためのnk−1受容体拮抗薬の使用
|
JP2001504852A
(ja)
*
|
1996-12-02 |
2001-04-10 |
メルク シヤープ エンド ドーム リミテツド |
双極性障害の治療のためのnk−1受容体拮抗薬の使用
|
ATE282417T1
(de)
*
|
1996-12-02 |
2004-12-15 |
Merck Sharp & Dohme |
Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
|
US5977104A
(en)
*
|
1996-12-02 |
1999-11-02 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating bipolar disorders
|
GB9700555D0
(en)
*
|
1997-01-13 |
1997-03-05 |
Merck Sharp & Dohme |
Therapeutic agents
|
AU744261B2
(en)
*
|
1997-04-24 |
2002-02-21 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating eating disorders
|
CA2298777A1
(en)
*
|
1997-08-04 |
1999-02-18 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating mania
|
GB9716463D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9716457D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
CA2298779A1
(en)
*
|
1997-08-04 |
1999-02-18 |
Merck Sharp & Dohme Limited |
Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
|
US6271230B1
(en)
|
1997-12-01 |
2001-08-07 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating cognitive disorders
|
US6087348A
(en)
*
|
1997-12-01 |
2000-07-11 |
Merck Sharp & Dohme Ltd. |
Use of NK-1 receptor antagonists for treating stress disorders
|
US6156749A
(en)
*
|
1997-12-01 |
2000-12-05 |
Merck Sharp & Dohme Limited |
Use of NK-1 receptor antagonists for treating movement disorders
|
US5972938A
(en)
*
|
1997-12-01 |
1999-10-26 |
Merck & Co., Inc. |
Method for treating or preventing psychoimmunological disorders
|
GB9810092D0
(en)
*
|
1998-05-11 |
1998-07-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
WO1999064006A1
(en)
*
|
1998-06-11 |
1999-12-16 |
Merck Sharp & Dohme Limited |
Use of a nk-1 receptor antagonist for treating psychiatric disorders
|
WO1999064010A1
(en)
*
|
1998-06-11 |
1999-12-16 |
Merck Sharp & Dohme Limited |
Use of a nk-1 receptor antagonist for treating psychiatric disorders
|
GB9812617D0
(en)
*
|
1998-06-11 |
1998-08-12 |
Merck Sharp & Dohme |
Therapeutic use
|
GB9812662D0
(en)
*
|
1998-06-11 |
1998-08-12 |
Merck Sharp & Dohme |
Therapeutic use
|
GB9812664D0
(en)
*
|
1998-06-11 |
1998-08-12 |
Merck Sharp & Dohme |
Therapeutic use
|
GB9813025D0
(en)
*
|
1998-06-16 |
1998-08-12 |
Merck Sharp & Dohme |
Chemical synthesis
|
GB9816897D0
(en)
*
|
1998-08-04 |
1998-09-30 |
Merck Sharp & Dohme |
Therapeutic use
|
WO2000026214A1
(en)
*
|
1998-10-30 |
2000-05-11 |
Merck & Co., Inc. |
Linear process for the preparation of a morpholine compound
|
EP1124826A1
(de)
*
|
1998-10-30 |
2001-08-22 |
Merck & Co., Inc. |
Verfahren zur herstellung von 2-(r)-(1-(r)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-((5-(dimethylaminomethyl)-1,2,3-triazol-4-yl)methyl)-3-(s)-(4-fluorophenyl)morpholin
|
DK1394150T3
(da)
*
|
1999-02-24 |
2011-03-21 |
Hoffmann La Roche |
4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
|
WO2000050398A2
(en)
|
1999-02-24 |
2000-08-31 |
F. Hoffmann-La Roche Ag |
Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists
|
JP4068305B2
(ja)
|
1999-02-24 |
2008-03-26 |
エフ.ホフマン−ラ ロシュ アーゲー |
3−フェニルピリジン誘導体、およびそのnk−1受容体拮抗薬としての用途
|
US6291465B1
(en)
|
1999-03-09 |
2001-09-18 |
Hoffmann-La Roche Inc. |
Biphenyl derivatives
|
TW550258B
(en)
|
1999-05-31 |
2003-09-01 |
Hoffmann La Roche |
4-phenyl-pyrimidine derivatives
|
JO2308B1
(en)
|
1999-05-31 |
2005-09-12 |
اف. هوفمان- لاروش أيه جي |
Derivatives of phenylpyrmidine
|
EP1228068A1
(de)
*
|
1999-10-29 |
2002-08-07 |
Merck & Co., Inc. |
Polymorphe form eines tachykininrezeptorantagonisten
|
DK1103545T3
(da)
*
|
1999-11-29 |
2004-03-15 |
Hoffmann La Roche |
2-(3,5-bis-trifluormethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
|
US6452001B2
(en)
|
2000-05-25 |
2002-09-17 |
Hoffmann-La Roche Inc. |
Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation
|
US6482829B2
(en)
|
2000-06-08 |
2002-11-19 |
Hoffmann-La Roche Inc. |
Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
|
AR030284A1
(es)
|
2000-06-08 |
2003-08-20 |
Merck & Co Inc |
Proceso para la sintesis de (2r, 2-alfa-r,3a) -2-[1-(3,5-bis(trifluorometil) fenil) etoxi]-3-(4-fluorofenil)-1,4-oxazina; dicho compuesto y sus formas polimorficas
|
WO2001096319A1
(en)
*
|
2000-06-09 |
2001-12-20 |
Merck & Co., Inc. |
Trans-glycosidation process for the synthesis of (2r, 2-alpha-r, 3a)-2-[1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-1,4-oxazine
|
KR100501608B1
(ko)
|
2000-07-14 |
2005-07-18 |
에프. 호프만-라 로슈 아게 |
4-페닐-피리딘 유도체의 nk1 수용체의 길항성선구약물로서의 n-산화물
|
TWI287003B
(en)
|
2000-07-24 |
2007-09-21 |
Hoffmann La Roche |
4-phenyl-pyridine derivatives
|
TWI259180B
(en)
|
2000-08-08 |
2006-08-01 |
Hoffmann La Roche |
4-Phenyl-pyridine derivatives
|
GB0020721D0
(en)
*
|
2000-08-22 |
2000-10-11 |
Merck Sharp & Dohme |
Therapeutic agents
|
YU39503A
(sh)
|
2000-11-22 |
2006-05-25 |
F. Hoffmann-La Roche Ag. |
Derivati pirimidina
|
US6642226B2
(en)
|
2001-02-06 |
2003-11-04 |
Hoffman-La Roche Inc. |
Substituted phenyl-piperidine methanone compounds
|
US6849624B2
(en)
|
2001-07-31 |
2005-02-01 |
Hoffmann-La Roche Inc. |
Aromatic and heteroaromatic substituted amides
|
US6638981B2
(en)
|
2001-08-17 |
2003-10-28 |
Epicept Corporation |
Topical compositions and methods for treating pain
|
CN100562320C
(zh)
|
2003-01-31 |
2009-11-25 |
弗·哈夫曼-拉罗切有限公司 |
2-(3,5-二-三氟甲基-苯基)-N-[6-(1,1-二氧代-1λ6-硫代吗啉-4-基)-4-(4-氟-2-甲基-苯基)-吡啶-3-基]-N-甲基-异丁酰胺的新晶体变体
|
EP1643998B1
(de)
|
2003-07-03 |
2007-08-29 |
F. Hoffmann-La Roche Ag |
Duale nk1/nk3 antagonisten zur behandlung von schizophrenie
|
TWI280239B
(en)
|
2003-07-15 |
2007-05-01 |
Hoffmann La Roche |
Process for preparation of pyridine derivatives
|
ES2246687B2
(es)
|
2004-02-11 |
2006-11-16 |
Miguel Muñoz Saez |
Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
|
ZA200701232B
(en)
|
2004-07-15 |
2008-08-27 |
Amr Technology Inc |
Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
|
CA2592605C
(en)
|
2004-12-27 |
2010-12-07 |
Eisai R&D Management Co., Ltd. |
Method for stabilizing anti-dementia drug
|
JP4767973B2
(ja)
|
2005-02-22 |
2011-09-07 |
エフ.ホフマン−ラ ロシュ アーゲー |
Nk1アンタゴニスト
|
DK1863767T3
(da)
|
2005-03-23 |
2009-05-04 |
Hoffmann La Roche |
Metabolitter til NK-I-antagonister til emesis
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
US7956050B2
(en)
|
2005-07-15 |
2011-06-07 |
Albany Molecular Research, Inc. |
Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
DK1928427T3
(da)
|
2005-09-23 |
2010-03-08 |
Hoffmann La Roche |
Hidtil ukendt dosisformulering
|
EP1940842B1
(de)
|
2005-09-29 |
2012-05-30 |
Merck Sharp & Dohme Corp. |
Acylierte spiropiperidinderivate als modulatoren des melanocortin-4-rezeptors
|
US8080656B2
(en)
|
2005-10-05 |
2011-12-20 |
Ranbaxy Laboratories Limited |
Process for the preparation of aprepitant
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
EP2698157B1
(de)
|
2006-09-22 |
2015-05-20 |
Merck Sharp & Dohme Corp. |
Verfahren zur Behandlung von Fettsäure-Synthese-Hemmern
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
EP2109608B1
(de)
|
2007-01-10 |
2011-03-23 |
Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. |
Amidsubstituierte indazole als poly-(adp-ribose)-polymerase (parp)-hemmer
|
EP2129381A1
(de)
|
2007-01-24 |
2009-12-09 |
Glaxo Group Limited |
Pharmazeutische zubereitungen enthaltend 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazin or r(-)-2,4-diamino-5-(2,3dichlorophenyl)-6-fluoromethyl pyrimidin und einen nk1- rezeptor-antagonisten
|
AU2008233662B2
(en)
|
2007-04-02 |
2012-08-23 |
Msd K.K. |
Indoledione derivative
|
DE602008001983D1
(de)
|
2007-04-20 |
2010-09-09 |
Hoffmann La Roche |
Pyrrolidinderivate als doppelte nk1/nk3-rezeptorenantagonisten
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
MX2010001080A
(es)
|
2007-08-07 |
2010-03-01 |
Hoffmann La Roche |
Pirrolidin-aril-eteres como antagonistas de receptor de nk3.
|
CA2716080C
(en)
|
2008-02-20 |
2016-12-13 |
Targia Pharmaceuticals |
Cns pharmaceutical compositions and methods of use
|
CN102014631A
(zh)
|
2008-03-03 |
2011-04-13 |
泰格尔医药科技公司 |
酪氨酸激酶抑制剂
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
EP2413932A4
(de)
|
2009-04-01 |
2012-09-19 |
Merck Sharp & Dohme |
Hemmer der akt-aktivität
|
CA2760837C
(en)
|
2009-05-12 |
2018-04-03 |
Albany Molecular Research, Inc. |
7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
|
WO2010132437A1
(en)
|
2009-05-12 |
2010-11-18 |
Albany Molecular Research, Inc. |
Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
|
JP5739415B2
(ja)
|
2009-05-12 |
2015-06-24 |
ブリストル−マイヤーズ スクウィブ カンパニー |
(S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用
|
EP2488028B1
(de)
|
2009-10-14 |
2020-08-19 |
Merck Sharp & Dohme Corp. |
Substituierte piperidine zur erhöhung der p53-aktivität und ihre verwendung
|
US8487102B2
(en)
|
2010-04-20 |
2013-07-16 |
Hoffmann-La Roche Inc. |
Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
CN103068980B
(zh)
|
2010-08-02 |
2017-04-05 |
瑟纳治疗公司 |
使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制
|
ES2376564B1
(es)
|
2010-08-12 |
2013-01-24 |
Manuel Vicente Salinas Martín |
Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer.
|
KR102072631B1
(ko)
|
2010-08-17 |
2020-02-03 |
시르나 쎄러퓨틱스 인코퍼레이티드 |
짧은 간섭 핵산 (siNA)을 사용한 B형 간염 바이러스 (HBV) 유전자 발현의 RNA 간섭 매개 억제
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
EP3766975A1
(de)
|
2010-10-29 |
2021-01-20 |
Sirna Therapeutics, Inc. |
Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US20140046059A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Process for the preparation of morpholino sulfonyl indole derivatives
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
EP2837381A4
(de)
|
2011-12-13 |
2015-12-09 |
Servicio Andaluz De Salud |
Verwendung von mitteln zur behandlung von krebs, die die peritumoralumgebung verändern
|
US20150299696A1
(en)
|
2012-05-02 |
2015-10-22 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
WO2014052563A2
(en)
|
2012-09-28 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
ES2651347T3
(es)
|
2012-11-28 |
2018-01-25 |
Merck Sharp & Dohme Corp. |
Composiciones y métodos para el tratamiento del cáncer
|
CA2895504A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
US9540377B2
(en)
|
2013-01-30 |
2017-01-10 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as HDM2 inhibitors
|
ES2493693B1
(es)
|
2013-02-11 |
2015-07-07 |
Servicio Andaluz De Salud |
Método para predecir o pronosticar la respuesta de un sujeto humano que padece un cáncer al tratamiento con un antagonista del receptor NK1
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
ES2541870B1
(es)
|
2013-12-27 |
2016-05-12 |
Servicio Andaluz De Salud |
Uso de antagonistas no peptídicos de NK1 en una determinada dosis para el tratamiento del cáncer
|
US20160324881A1
(en)
*
|
2013-12-30 |
2016-11-10 |
Oncoprevent Gmbh |
Neurokinin-1 Receptor Antagonists For Use In A Method Of Prevention Of Cancer
|
TW201613888A
(en)
|
2014-09-26 |
2016-04-16 |
Helsinn Healthcare Sa |
Crystalline forms of an NK-1 antagonist
|
US10005803B2
(en)
|
2015-10-06 |
2018-06-26 |
Helsinn Healthcare Sa |
Crystalline forms of fosnetupitant
|
EP3435980B1
(de)
|
2016-06-06 |
2019-11-13 |
Helsinn Healthcare SA |
Physiologisch ausgewogene injizierbare formulierungen von fosnetupitant
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|